Indications for Implantable Cardioverter Defibrillators

  • Salam Sbaity
  • Brian Olshansky

Sudden death caused by cardiac arrest due to ventricular tachycardia or ventricular fibrillation remains a serious health problem worldwide. In the United States alone, cardiovascular disease accounts for over 900,000 deaths annually (1). Of these deaths, 350,000 are due to out-of-hospital cardiac arrest (2), two-thirds of which occur without prior recognition of cardiac disease (1). In the United States, 15–20% of all fatalities and 50% of all cardiac fatalities are sudden. Although sudden death caused by asystole or pulseless electrical activity is not preventable, sudden death caused by a ventricular arrhythmia can be. Prompt treatment to stop the ventricular arrhythmia before it causes death is possible.


Ventricular Tachycardia Antiarrhythmic Drug Nonsustained Ventricular Tachycardia Implantable Defibrillator Implantable Cardioverter Defibrillator Implantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thom, T., et al., Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2006. 113(6): p. e85–151.PubMedCrossRefGoogle Scholar
  2. 2.
    Rea, T.D., et al., Incidence of EMS-treated out-of-hospital cardiac arrest in the United States. Resuscitation, 2004. 63(1): p. 17–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Lopshire, J.C. and D.P. Zipes, Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation, 2006. 114(11): p. 1134–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Broadley, A.J., et al., Baroreflex sensitivity is reduced in depression. Psychosom Med, 2005. 67(4): p. 648–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Liu, Y.B., et al., Dyslipidemia is associated with ventricular tachyarrhythmia in patients with acute ST-segment elevation myocardial infarction. J Formos Med Assoc = Taiwan yi zhi, 2006. 105(1): p. 17–24.Google Scholar
  6. 6.
    James, A.F., S.C. Choisy, and J.C. Hancox, Recent advances in understanding sex differences in cardiac repolarization, 2007. 94: p. 265–319.Google Scholar
  7. 7.
    Russo, A.M., et al., Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. J Cardiovasc Electrophysiol, 2004. 15(9): p. 993–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lampert, R., et al., Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators. J Am Coll Cardiol, 2004. 43(12): p. 2293–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Wolbrette, D., et al., Gender differences in arrhythmias. Clin Cardiol, 2002. 25(2): p. 49–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Thorgeirsson, G., et al., Risk factors for out-of-hospital cardiac arrest: the Reykjavik Study. Eur Heart J, 2005. 26(15): p. 1499–505.PubMedCrossRefGoogle Scholar
  11. 11.
    Locati, E.H., et al., Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation, 1998. 97(22): p. 2237–44.PubMedGoogle Scholar
  12. 12.
    Moise, N.S., et al., Age dependence of the development of ventricular arrhythmias in a canine model of sudden cardiac death. Cardiovasc Res, 1997. 34(3): p. 483–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Goldenberg, I., et al., Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med, 2003. 163(19): p. 2301–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Diamond, J.A. and R.A. Phillips, Hypertensive heart disease. Hypertension research, 2005. 28(3): p. 191–202.PubMedCrossRefGoogle Scholar
  15. 15.
    Holzgreve, H., Benefits of antihypertensive treatment. How much damage does it really prevent? MMW Fortschritte der Medizin, 2006. 148(14): p. 47, 49–50.PubMedGoogle Scholar
  16. 16.
    Bray, G.A. and T. Bellanger, Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine, 2006. 29(1): p. 109–17.PubMedCrossRefGoogle Scholar
  17. 17.
    Wheelan, K., et al., Sudden death and its relation to QT-interval prolongation after acute myocardial infarction: two-year follow-up. Am J Cardiol, 1986. 57(10): p. 745–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Pagnoni, F., et al., Long-term prognostic significance and electrophysiological evolution of intraventricular conduction disturbances complicating acute myocardial infarction. Pacing and clinical electrophysiology, 1986. 9(1 Pt 1): p. 91–100.PubMedCrossRefGoogle Scholar
  19. 19.
    Kaufman, E.S., et al., “Indeterminate” microvolt T-wave alternans tests predict high risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol, 2006. 48(7): p. 1399–404.PubMedCrossRefGoogle Scholar
  20. 20.
    Naccarelli, G.V. and M.A. Lukas, Carvedilol’s antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol, 2005. 28(4): p. 165–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Hagens, V.E., et al., Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. Am J Cardiol, 2006. 98(7): p. 929–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Pedersen, O.D., et al., Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J, 2006. 27(3): p. 290–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Underwood, R.D., J. Sra, and M. Akhtar, Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. Clin Cardiol, 1997. 20(9): p. 753–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Middlekauff, H.R., W.G. Stevenson, and L.A. Saxon, Prognosis after syncope: impact of left ventricular function. Am Heart J, 1993. 125(1): p. 121–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Vester, E.G., et al., Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J, 1992. 13(Suppl D): p. 70–81.PubMedGoogle Scholar
  26. 26.
    Buxton, A.E., et al., Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiologic study. Circulation, 1987. 75(6): p. 1178–85.PubMedGoogle Scholar
  27. 27.
    Tan, H.L., et al., Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation, 2005. 112(2): p. 207–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Lind, J.M., C. Chiu, and C. Semsarian, Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther, 2006. 4(6): p. 927–34.CrossRefGoogle Scholar
  29. 29.
    Kirchhof, P., G. Breithardt, and L. Eckardt, Primary prevention of sudden cardiac death. Heart, 2006. 92(12): p. 1873–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Nishio, H., M. Iwata, and K. Suzuki, Postmortem molecular screening for cardiac ryanodine receptor type 2 mutations in sudden unexplained death: R420W mutated case with characteristics of status thymico-lymphatics. Circ J, 2006. 70(11): p. 1402–6.CrossRefGoogle Scholar
  31. 31.
    Bar-Cohen, Y. and M.J. Silka, Congenital long QT syndrome: diagnosis and management in pediatric patients. Curr Treat Options Cardiovasc Med, 2006. 8(5): p. 387–395.PubMedCrossRefGoogle Scholar
  32. 32.
    Postma, A.V., Z.A. Bhuiyan, and H. Bikker, Molecular diagnostics of catecholaminergic polymorphic ventricular tachycardia using denaturing high-performance liquid chromatography and sequencing. Methods Mol Med, 2006. 126: p. 171–83.Google Scholar
  33. 33.
    Modell, S.M. and M.H. Lehmann, The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med, 2006. 8(3): p. 143–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Calkins, H., Arrhythmogenic right-ventricular dysplasia/cardiomyopathy. Curr Opin Cardiol, 2006. 21(1): p. 55–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Podrid, P.J. and R.J. Myerburg, Epidemiology and stratification of risk for sudden cardiac death. Clinical cardiology, 2005. 28(11 Suppl 1): p. I3–11.PubMedGoogle Scholar
  36. 36.
    Corrado, D., et al., Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation, 2003. 108(25): p. 3084–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Spooner, P.M. and D.P. Zipes, Sudden death predictors: an inflammatory association. Circulation, 2002. 105(22): p. 2574–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Burke, A.P., et al., Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation, 2002. 105(17): p. 2019–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Biasucci, L.M., et al., C reactive protein is associated with malignant ventricular arrhythmias in patients with ischaemia with implantable cardioverter-defibrillator. Heart, 2006. 92(8): p. 1147–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Bikkina, M., M.G. Larson, and D. Levy, Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med, 1992. 117(12): p. 990–6.PubMedGoogle Scholar
  41. 41.
    Buxton, A.E., et al., Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol, 1984. 53(9): p. 1275–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Wilber, D.J., et al., Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation, 1990. 82(2): p. 350–8.PubMedGoogle Scholar
  43. 43.
    Bigger, J.T., Jr., et al., The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation, 1984. 69(2): p. 250–8.PubMedGoogle Scholar
  44. 44.
    Maggioni, A.P., et al., Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation, 1993. 87(2): p. 312–22.PubMedGoogle Scholar
  45. 45.
    Schmidt, G., et al., Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet, 1999. 353(9162): p. 1390–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Ghuran, A., et al., Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (The Autonomic Tone and Reflexes After Myocardial Infarction substudy). Am J Cardiol, 2002. 89(2): p. 184–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Barthel, P., et al., Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation, 2003. 108(10): p. 1221–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Smith, J.M., et al., Electrical alternans and cardiac electrical instability. Circulation, 1988. 77(1): p. 110–21.PubMedGoogle Scholar
  49. 49.
    Estes, N.A., 3rd, et al., Electrical alternans during rest and exercise as predictors of vulnerability to ventricular arrhythmias. Am J Cardiol, 1997. 80(10): p. 1314–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Rosenbaum, D.S., et al., Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med, 1994. 330(4): p. 235–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Narayan, S.M. and J.M. Smith, Exploiting rate-related hysteresis in repolarization alternans to improve risk stratification for ventricular tachycardia. J Am Coll Cardiol, 2000. 35(6): p. 1485–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Bluzaite, I., et al., QT dispersion and heart rate variability in sudden death risk stratification in patients with ischemic heart disease. Medicina (Kaunas), 2006. 42(6): p. 450–4.Google Scholar
  53. 53.
    Dinckal, M.H., et al., QT dispersion in the risk stratification of patients with unstable angina: correlation with clinical course, troponin T and scintigraphy. Acta Cardiol, 2004. 59(3): p. 283–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Bardy, G.H., et al., Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005. 352(3): p. 225–37.PubMedCrossRefGoogle Scholar
  55. 55.
    Iravanian, S., A. Arshad, and J.S. Steinberg, Role of electrophysiologic studies, signal-averaged electrocardiography, heart rate variability, T-wave alternans, and loop recorders for risk stratification of ventricular arrhythmias. Am J Geriatr Cardiol, 2005. 14(1): p. 16–9.CrossRefGoogle Scholar
  56. 56.
    Lander, P., et al., Critical analysis of the signal-averaged electrocardiogram. Improved identification of late potentials. Circulation, 1993. 87(1): p. 105–17.PubMedGoogle Scholar
  57. 57.
    Rozanski, J.J. and M. Kleinfeld, Alternans of the ST segment of T wave. A sign of electrical instability in Prinzmetal’s angina. Pacing Clin Electrophysiol, 1982. 5(3): p. 359–65.CrossRefGoogle Scholar
  58. 58.
    Bloomfield, D.M., et al., Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation, 2004. 110(14): p. 1885–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Gold, M.R., et al., T-Wave Alternans SCD HeFT Study: Primary Endpoint Analysis. Circulation, 2006. 114: p. II-428–9.Google Scholar
  60. 60.
    Akhtar, M., et al., Sudden cardiac death: management of high-risk patients. Ann Intern Med, 1991. 114(6): p. 499–512.PubMedGoogle Scholar
  61. 61.
    Olshansky, B., M. Mazuz, and J.B. Martins, Significance of inducible tachycardia in patients with syncope of unknown origin: a long-term follow-up. J Am Coll Cardiol, 1985. 5(2 Pt 1): p. 216–23.Google Scholar
  62. 62.
    Mitchell, L.B., et al., A randomized clinical trial of the noninvasive and invasive approaches to drug therapy for ventricular tachycardia: long-term follow-up of the Calgary trial. Prog Cardiovasc Dis, 1996. 38(5): p. 377–84.PubMedCrossRefGoogle Scholar
  63. 63.
    Steinbeck, G., et al., A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med, 1992. 327(14): p. 987–92.PubMedGoogle Scholar
  64. 64.
    Richards, D.A., et al., Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol, 1983. 51(1): p. 75–80.PubMedCrossRefGoogle Scholar
  65. 65.
    Bourke, J.P., et al., Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol, 1991. 18(3): p. 780–8.PubMedGoogle Scholar
  66. 66.
    Zoni-Berisso, M., et al., Value of programmed ventricular stimulation in predicting sudden death and sustained ventricular tachycardia in survivors of acute myocardial infarction. Am J Cardiol, 1996. 77(9): p. 673–80.PubMedCrossRefGoogle Scholar
  67. 67.
    Behr, E.R., P. Elliott, and W.J. McKenna, Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev, 2002. 6(4): p. 482–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Kuck, K.H., et al., Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J, 1988. 9(2): p. 177–85.Google Scholar
  69. 69.
    Buxton, A.E., et al., Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. New Engl J Med, 2000. 342(26): p. 1937–45.PubMedCrossRefGoogle Scholar
  70. 70.
    Freedman, R.A., et al., Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. Am J Cardiol, 1988. 61(8): p. 578–82.PubMedCrossRefGoogle Scholar
  71. 71.
    Mason, J.W., A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. New Engl J Med, 1993. 329(7): p. 445–51.Google Scholar
  72. 72.
    Moss, A.J., et al., Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. New Engl J Med, 1996. 335(26): p. 1933–40.PubMedCrossRefGoogle Scholar
  73. 73.
    A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. New Engl J Med, 1997. 337(22): p. 1576–83.Google Scholar
  74. 74.
    Brembilla-Perrot, B., et al., Programmed ventricular stimulation in survivors of acute myocardial infarction: long-term follow-up. Int J Cardiol, 1995. 49(1): p. 55–65.PubMedCrossRefGoogle Scholar
  75. 75.
    Bourke, J.P., et al., Does the induction of ventricular flutter or fibrillation at electrophysiologic testing after myocardial infarction have any prognostic significance? Am J Cardiol, 1995. 75(7): p. 431–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Zipes, D.P., et al., ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol, 2006. 48(5): p. 1064–108.CrossRefGoogle Scholar
  77. 77.
    Nademanee, K., et al., Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation, 2003. 107(17): p. 2221–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Gottlieb, S.S., R.J. McCarter, and R.A. Vogel, Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med, 1998. 339(8): p. 489–97.PubMedCrossRefGoogle Scholar
  79. 79.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 1999. 353(9146): p. 9–13.Google Scholar
  80. 80.
    Makikallio, T.H., et al., Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol, 2006. 97(4): p. 480–4.PubMedCrossRefGoogle Scholar
  81. 81.
    Bauer, A., et al., Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era. Eur Heart J, 2005. 26(8): p. 755–61.PubMedCrossRefGoogle Scholar
  82. 82.
    Young, J.B., et al., Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA, 2003. 289(20): p. 2685–94.PubMedCrossRefGoogle Scholar
  83. 83.
    Domanski, M.J., et al., Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol, 1999. 33(3): p. 598–604.PubMedCrossRefGoogle Scholar
  84. 84.
    Fonseca, V.A., Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease. J Clin Hypertens (Greenwich), 2006. 8(10): p. 713–20; quiz 721–2.CrossRefGoogle Scholar
  85. 85.
    Susan, M., et al., Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function. Rom J Intern Med = Revue roumaine de medecine interne, 2005. 43(3–4): p. 187–98.Google Scholar
  86. 86.
    McMurray, J., et al., Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) Trial. J Am Coll Cardiol, 2005. 45(4): p. 525–30.PubMedCrossRefGoogle Scholar
  87. 87.
    Pelargonio, G. and E.N. Prystowsky, Rate versus rhythm control in the management of patients with atrial fibrillation. Nature clinical practice, 2005. 2(10): p. 514–21.PubMedCrossRefGoogle Scholar
  88. 88.
    Taylor, F.C., H. Cohen, and S. Ebrahim, Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. Br Med J (Clin Res Ed, 2001. 322(7282): p. 321–6.Google Scholar
  89. 89.
    Peverill, R.E., Warfarin or aspirin: both or others? Med J Aust, 1999. 171(6): p. 321–6.PubMedGoogle Scholar
  90. 90.
    Kottkamp, H., G. Hindricks, and G. Breithardt, Role of anticoagulant therapy in atrial fibrillation. J Cardiovasc Electrophysiol, 1998. 9(8 Suppl): p. S86–96.PubMedGoogle Scholar
  91. 91.
    Cleland, J.G., et al., Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. Eur J Heart Fail, 2003. 5(3): p. 391–8.Google Scholar
  92. 92.
    Chiu, J.H., et al., Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol, 2005. 95(4): p. 490–1.PubMedCrossRefGoogle Scholar
  93. 93.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999. 353(9169): p. 2001–7.Google Scholar
  94. 94.
    Dargie, H.J., Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001. 357(9266): p. 1385–90.PubMedCrossRefGoogle Scholar
  95. 95.
    Yusuf, S., et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000. 342(3): p. 145–53.PubMedCrossRefGoogle Scholar
  96. 96.
    Teo, K.K., et al., Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation, 2004. 110(11): p. 1413–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Pitt, B., et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999. 341(10): p. 709–17.PubMedCrossRefGoogle Scholar
  98. 98.
    Pitt, B., et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003. 348(14): p. 1309–21.PubMedCrossRefGoogle Scholar
  99. 99.
    Zijlstra, F. and I.C. van der Horst, Sudden death in patients with myocardial infarction. N Engl J Med, 2005. 353(12): p. 1294–7; author reply 1294–7.Google Scholar
  100. 100.
    Zaliunas, R., et al., Cardiac events and 5-year survival after acute coronary syndromes. Medicina (Kaunas), 2005. 41(8): p. 668–74.Google Scholar
  101. 101.
    Antezano, E.S. and M. Hong, Sudden cardiac death. J Intensive Care Med, 2003. 18(6): p. 313–29.PubMedCrossRefGoogle Scholar
  102. 102.
    Germing, A., et al., Clinical and angiographic results of coronary artery stenting using PURA-VARIO (PUVA) stents. Int J Cardiovasc Intervent, 2003. 5(3): p. 156–60.PubMedCrossRefGoogle Scholar
  103. 103.
    Bradshaw, P.J., et al., Mortality and recurrent cardiac events after coronary artery bypass graft: long term outcomes in a population study. Heart, 2002. 88(5): p. 488–94.PubMedCrossRefGoogle Scholar
  104. 104.
    Elbaz, M., et al., Is direct coronary stenting the best strategy for long-term outcome? Results of the multicentric randomized benefit evaluation of direct coronary stenting (BET) study. Am Heart J, 2002. 144(4): p. E7.Google Scholar
  105. 105.
    Every, N., et al., Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. Am Heart J, 2002. 144(3): p. 390–6.PubMedCrossRefGoogle Scholar
  106. 106.
    Mittal, S., et al., Prognostic significance of nonsustained ventricular tachycardia after revascularization. J Cardiovasc Electrophysiol, 2002. 13(4): p. 342–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Uerojanaungkul, P., et al., Short and intermediate clinical outcome after late coronary stenting in myocardial infarction. J Med Assoc Thai, 2001. 84(7): p. 948–57.PubMedGoogle Scholar
  108. 108.
    Jessup, M. and S. Brozena, Heart failure. N Engl J Med, 2003. 348(20): p. 2007–18.PubMedCrossRefGoogle Scholar
  109. 109.
    Bigger, J.T., Jr., Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation, 1987. 75(5 Pt 2): p. IV28–35.PubMedGoogle Scholar
  110. 110.
    Singh, S.N., et al., Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. New Engl J Med, 1995. 333(2): p. 77–82.PubMedCrossRefGoogle Scholar
  111. 111.
    Rogers, W.J., et al., Quality of life among 5, 025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol, 1994. 23(2): p. 393–400.PubMedCrossRefGoogle Scholar
  112. 112.
    Segev, A. and Y.A. Mekori, The Cardiac Insufficiency Bisoprolol Study II. Lancet, 1999. 353(9161): p. 1361.PubMedCrossRefGoogle Scholar
  113. 113.
    Gheorghiade, M. and B. Pitt, Digitalis Investigation Group (DIG) trial: a stimulus for further research. American heart journal, 1997. 134(1): p. 3–12.PubMedCrossRefGoogle Scholar
  114. 114.
    Packer, M., et al., Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New Engl J Med, 1991. 325(21): p. 1468–75.PubMedCrossRefGoogle Scholar
  115. 115.
    De Sutter, J., et al., Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol, 2000. 36(3): p. 766–72.PubMedCrossRefGoogle Scholar
  116. 116.
    Waldo, A.L., et al., Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-Sotalol. Lancet, 1996. 348(9019): p. 7–12.PubMedCrossRefGoogle Scholar
  117. 117.
    Farre, J., et al., Amiodarone and “primary” prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol, 1999. 83(5B): p. 55D–63D.PubMedCrossRefGoogle Scholar
  118. 118.
    A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med, 1997. 337(22): p. 1576–83.Google Scholar
  119. 119.
    Buxton, A.E., et al., A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med, 1999. 341(25): p. 1882–90.PubMedCrossRefGoogle Scholar
  120. 120.
    Capucci, A., D. Aschieri, and G.Q. Villani, The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD’s. J Interv Card Electrophysiol, 2000. 4(Suppl 1): p. 57–63.PubMedCrossRefGoogle Scholar
  121. 121.
    Lau, E.W., et al., The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death. Europace, 2004. 6(4): p. 257–66.PubMedCrossRefGoogle Scholar
  122. 122.
    Julian, D.G., et al., Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet, 1997. 349(9053): p. 667–74.PubMedCrossRefGoogle Scholar
  123. 123.
    Cairns, J.A., et al., Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet, 1997. 349(9053): p. 675–82.CrossRefGoogle Scholar
  124. 124.
    Camm, A.J., et al., Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation, 2004. 109(8): p. 990–6.PubMedCrossRefGoogle Scholar
  125. 125.
    Ruskin, J.N., The cardiac arrhythmia suppression trial (CAST). New Engl J Med, 1989. 321(6): p. 386–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Anderson, J.L., et al., Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation, 1994. 90(6): p. 2843–52.Google Scholar
  127. 127.
    Brooks, M.M., et al., Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II). Control Clin Trials, 1994. 15(6): p. 437–49.PubMedCrossRefGoogle Scholar
  128. 128.
    The Cardiac Arrhythmia Suppression Trial II Investigators, Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med, 1992. 327(4): p. 227–33.Google Scholar
  129. 129.
    Greene, H.L., et al., The Cardiac Arrhythmia Suppression Trial: first CAST… then CAST-II. J Am Coll Cardiol, 1992. 19(5): p. 894–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Impact Research Group, International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol, 1984. 4(6): p. 1148–63.Google Scholar
  131. 131.
    Mason, J.W., A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. New Engl J Med, 1993. 329(7): p. 452–8.Google Scholar
  132. 132.
    Omoigui, N.A., et al., Cost of initial therapy in the Electrophysiological Study Versus ECG Monitoring trial (ESVEM). Circulation, 1995. 91(4): p. 1070–6.PubMedGoogle Scholar
  133. 133.
    Burkart, F., et al., Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol, 1990. 16(7): p. 1711–8.PubMedCrossRefGoogle Scholar
  134. 134.
    Doval, H.C., et al., Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet, 1994. 344(8921): p. 493–8.CrossRefGoogle Scholar
  135. 135.
    Sim, I., et al., Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation, 1997. 96(9): p. 2823–9.PubMedGoogle Scholar
  136. 136.
    Steinberg, J.S., et al., Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J, 2001. 142(3): p. 520–9.PubMedCrossRefGoogle Scholar
  137. 137.
    Camm, A.J., R. Karam, and C.M. Pratt, The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol, 1998. 81(6A): p. 35D–39D.PubMedCrossRefGoogle Scholar
  138. 138.
    Stevenson, W.G., et al., Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation, 1993. 88(4 Pt 1): p. 1647–70.PubMedGoogle Scholar
  139. 139.
    Hindricks, G., The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias. The Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on Arrhythmias of the European Society of Cardiology. European heart journal, 1993. 14(12): p. 1644–53.Google Scholar
  140. 140.
    Morady, F., et al., Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation, 1993. 87(2): p. 363–72.PubMedGoogle Scholar
  141. 141.
    Gonska, B.D., et al., Catheter ablation of ventricular tachycardia in 136 patients with coronary artery disease: results and long-term follow-up. J Am Coll Cardiol, 1994. 24(6): p. 1506–14.PubMedCrossRefGoogle Scholar
  142. 142.
    Blanck, Z., et al., Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol, 1993. 4(3): p. 253–62.PubMedCrossRefGoogle Scholar
  143. 143.
    Lau, C.P., Radiofrequency ablation of fascicular tachycardia: efficacy of pace-mapping and implications on tachycardia origin. Int J Cardiol, 1994. 46(3): p. 255–65.PubMedCrossRefGoogle Scholar
  144. 144.
    Bennett, D.H., Experience with radiofrequency catheter ablation of fascicular tachycardia. Heart, 1997. 77(2): p. 104–7.PubMedGoogle Scholar
  145. 145.
    Bogun, F., et al., Role of Purkinje fibers in post-infarction ventricular tachycardia. J Am Coll Cardiol, 2006. 48(12): p. 2500–7.PubMedCrossRefGoogle Scholar
  146. 146.
    Morady, F., et al., Concealed entrainment as a guide for catheter ablation of ventricular tachycardia in patients with prior myocardial infarction. J Am Coll Cardiol, 1991. 17(3): p. 678–89.PubMedCrossRefGoogle Scholar
  147. 147.
    Daoud, E. and F. Morady, Catheter ablation of ventricular tachycardia. Curr Opin Cardiol, 1995. 10(1): p. 21–5.PubMedCrossRefGoogle Scholar
  148. 148.
    Bansch, D., et al., Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation, 2002. 105(12): p. 1453–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Della Bella, P., Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Ital Heart J Suppl, 2000. 1(8): p. 1070–1.Google Scholar
  150. 150.
    Mirowski, M., et al., Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. New Engl J Med, 1980. 303(6): p. 322–4.PubMedCrossRefGoogle Scholar
  151. 151.
    Bocker, D., et al., Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J, 1995. 73(2): p. 158–63.PubMedCrossRefGoogle Scholar
  152. 152.
    Winkle, R.A., et al., Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol, 1989. 13(6): p. 1353–61.PubMedCrossRefGoogle Scholar
  153. 153.
    Fogoros, R.N., et al., Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol, 1990. 16(2): p. 381–6.PubMedCrossRefGoogle Scholar
  154. 154.
    Nisam, S., et al., AICD automatic cardioverter defibrillator clinical update: 14 years experience in over 34, 000 patients. Pacing and clinical electrophysiology, 1995. 18(1 Pt 2): p. 142–7.PubMedCrossRefGoogle Scholar
  155. 155.
    Connolly, S.J. and S. Yusuf, Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. Am J Cardiol, 1992. 69(9): p. 959–62.PubMedCrossRefGoogle Scholar
  156. 156.
    Epstein, A.E., AVID necessity. Pacing and clinical electrophysiology, 1993. 16(9): p. 1773–5.PubMedCrossRefGoogle Scholar
  157. 157.
    Kim, S.G., Implantable defibrillator therapy: does it really prolong life? How can we prove it? Am J Cardiol, 1993. 71(13): p. 1213–8.PubMedCrossRefGoogle Scholar
  158. 158.
    Luderitz, B., et al., Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol, 1993. 16(9): p. 1815–21.PubMedCrossRefGoogle Scholar
  159. 159.
    Kadish, A., et al., Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med, 2004. 350(21): p. 2151–8.PubMedCrossRefGoogle Scholar
  160. 160.
    Eicken, A., et al., Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol, 2006. 107(1): p. 30–5.PubMedCrossRefGoogle Scholar
  161. 161.
    Groeneveld, P.W., et al., Costs and quality-of-life effects of implantable cardioverter-defibrillators. Am J Cardiol, 2006. 98(10): p. 1409–15.PubMedCrossRefGoogle Scholar
  162. 162.
    Stevenson, L.W., Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks? Circulation, 2006. 114(2): p. 101–3.PubMedCrossRefGoogle Scholar
  163. 163.
    Alter, P., et al., Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol, 2005. 28(9): p. 926–32.PubMedCrossRefGoogle Scholar
  164. 164.
    Gould, P.A. and A.D. Krahn, Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA, 2006. 295(16): p. 1907–11.CrossRefGoogle Scholar
  165. 165.
    Maisel, W.H., et al., Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA, 2006. 295(16): p. 1901–6.PubMedCrossRefGoogle Scholar
  166. 166.
    Heller, S.S., et al., Psychosocial outcome after ICD implantation: a current perspective. Pacing Clin Electrophysiol, 1998. 21(6): p. 1207–15.PubMedCrossRefGoogle Scholar
  167. 167.
    Pires, L.A., et al., Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. Am Heart J, 2006. 151(4): p. 837–43.PubMedCrossRefGoogle Scholar
  168. 168.
    Lombardi, G., J. Gallagher, and P. Gennis, Outcome of out-of-hospital cardiac arrest in New York City. The Pre-Hospital Arrest Survival Evaluation (PHASE) Study. JAMA, 1994. 271(9): p. 678–83.CrossRefGoogle Scholar
  169. 169.
    Becker, L.B., et al., Outcome of CPR in a large metropolitan area–where are the survivors? Ann Emerg Med, 1991. 20(4): p. 355–61.PubMedCrossRefGoogle Scholar
  170. 170.
    Kuck, K.H., et al., Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation, 2000. 102(7): p. 748–54.PubMedGoogle Scholar
  171. 171.
    Connolly, S.J., et al., Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation, 2000. 101(11): p. 1297–302.PubMedGoogle Scholar
  172. 172.
    Moss, A.J., et al., Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 2002. 346(12): p. 877–83.PubMedCrossRefGoogle Scholar
  173. 173.
    Bigger, J.T., Jr., Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med, 1997. 337(22): p. 1569–75.CrossRefGoogle Scholar
  174. 174.
    Hohnloser, S.H., et al., Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med, 2004. 351(24): p. 2481–8.PubMedCrossRefGoogle Scholar
  175. 175.
    Buxton, A.E., et al., Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Progress in cardiovascular diseases, 1993. 36(3): p. 215–26.PubMedCrossRefGoogle Scholar
  176. 176.
    Strickberger, S.A., et al., Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol, 2003. 41(10): p. 1707–12.PubMedCrossRefGoogle Scholar
  177. 177.
    Desai, A.S., et al., Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA, 2004. 292(23): p. 2874–9.PubMedCrossRefGoogle Scholar
  178. 178.
    Lehmann, M.H. and S. Saksena, Implantable cardioverter defibrillators in cardiovascular practice: report of the Policy Conference of the North American Society of Pacing and Electrophysiology. NASPE Policy Conference Committee. Pacing Clin Electrophysiol, 1991. 14(6): p. 969–79.CrossRefGoogle Scholar
  179. 179.
    Gregoratos, G., et al., ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol, 1998. 31(5): p. 1175–209.PubMedCrossRefGoogle Scholar
  180. 180.
    Gregoratos, G., et al., ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol, 2002. 40(9): p. 1703–19.PubMedCrossRefGoogle Scholar
  181. 181.
    Zipes, D.P., et al., ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol, 2006. 48(5): p. e247–346.PubMedCrossRefGoogle Scholar
  182. 182.
    Flaker, G.C., In cardiac arrest: is a low K or a high K “okay?” J Cardiovasc Electrophysiol, 2001. 12(10): p. 1113–4.CrossRefGoogle Scholar
  183. 183.
    Todd, G.J. and G.F. Tyers, Potassium-induced arrest of the heart: effect of low potassium concentration. Surg Forum, 1975. 26: p. 255–6.PubMedGoogle Scholar
  184. 184.
    Knight, B.P., et al., Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol, 1999. 33(7): p. 1964–70.PubMedCrossRefGoogle Scholar
  185. 185.
    Middlekauff, H.R., et al., Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol, 1993. 21(1): p. 110–6.PubMedCrossRefGoogle Scholar
  186. 186.
    Maisel, W.H., et al., Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. JAMA, 2001. 286(7): p. 793–9.PubMedCrossRefGoogle Scholar
  187. 187.
    Weerasooriya, R., et al., Catheter ablation of ventricular fibrillation in structurally normal hearts targeting the RVOT and Purkinje ectopy. Herz, 2003. 28(7): p. 598–606.PubMedCrossRefGoogle Scholar
  188. 188.
    Haissaguerre, M., et al., Mapping and ablation of idiopathic ventricular fibrillation. Circulation, 2002. 106(8): p. 962–7.PubMedCrossRefGoogle Scholar
  189. 189.
    Wilkoff, B.L., et al., Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA, 2002. 288(24): p. 3115–23.PubMedCrossRefGoogle Scholar
  190. 190.
    Olshansky, B., et al., Reduction of right ventricular pacing in patients with dual-chamber ICDs. Pacing Clin Electrophysiol, 2006. 29(3): p. 237–43.PubMedCrossRefGoogle Scholar
  191. 191.
    Olshansky, B., et al., Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs (INTRINSIC RV): design and clinical protocol. Pacing Clin Electrophysiol, 2005. 28(1): p. 62–6.PubMedCrossRefGoogle Scholar
  192. 192.
    Olshansky, B., et al., Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter defibrillator? Results of the Intrinsic RV Study. Circulation, 2007. 115(1): p. 9–16.PubMedCrossRefGoogle Scholar
  193. 193.
    Wilkoff, B.L., et al., A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol, 2006. 48(2): p. 330–9.PubMedCrossRefGoogle Scholar
  194. 194.
    Cleland, J.G., et al., The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med, 2005. 352(15): p. 1539–49.PubMedCrossRefGoogle Scholar
  195. 195.
    Cleland, J.G., et al., Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail, 2005. 7(2): p. 205–14.PubMedCrossRefGoogle Scholar
  196. 196.
    Salukhe, T.V., K. Dimopoulos, and D. Francis, Cardiac resynchronisation may reduce all-cause mortality: meta-analysis of preliminary COMPANION data with CONTAK-CD, InSync ICD, MIRACLE and MUSTIC. Int J Cardiol, 2004. 93(2–3): p. 101–3.CrossRefGoogle Scholar
  197. 197.
    Bristow, M.R., A.M. Feldman, and L.A. Saxon, Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail, 2000. 6(3): p. 276–85.CrossRefGoogle Scholar
  198. 198.
    Abraham, W.T., et al., Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation, 2004. 110(18): p. 2864–8.PubMedCrossRefGoogle Scholar
  199. 199.
    Carnes, C.A., A.A. Mehdirad, and S.D. Nelson, Drug and defibrillator interactions. Pharmacotherapy, 1998. 18(3): p. 516–25.Google Scholar
  200. 200.
    Bardy, G.H., et al., Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device. Circulation, 1992. 85(5): p. 1689–98.PubMedGoogle Scholar
  201. 202.
    Rao, H.B. and S. Saksena, Implantable defibrillators configured for hybrid therapy of persistent and permanent atrial fibrillation: initial clinical experience with a novel lead system. Journal of interventional cardiac electrophysiology, 2005. 13 Suppl 1: p. 79–86.Google Scholar
  202. 202.
    Pacifico, A., et al., Prevention of implantable-defibrillator shocks by treatment with sotalol. d, l-Sotalol Implantable Cardioverter-Defibrillator Study Group. New Engl J Med, 1999. 340(24): p. 1855–62.CrossRefGoogle Scholar
  203. 203.
    Mason, J.W., et al., Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapy. Am Heart J, 1982. 103(4 Pt 2): p. 633–9.PubMedCrossRefGoogle Scholar
  204. 204.
    Podczeck, A., et al., Termination of re-entrant ventricular tachycardia by subthreshold stimulus applied to the zone of slow conduction. Eur Heart J, 1988. 9(10): p. 1146–50.PubMedGoogle Scholar
  205. 205.
    Kawanishi, D.T., et al., Cumulative hazard analysis of J-wire fracture in the Accufix series of atrial permanent pacemaker leads. Pacing Clin Electrophysiol, 1998. 21(11 Pt 2): p. 2322–6.PubMedCrossRefGoogle Scholar
  206. 206.
    Saksena, S., Antiarrhythmic device advisories and recalls: managing an increasingly vulnerable process. Pacing Clin Electrophysiol, 1999. 22(6 Pt 1): p. 950–2.PubMedCrossRefGoogle Scholar
  207. 207.
    Hauser, R.G. and L. Kallinen, Deaths associated with implantable cardioverter defibrillator failure and deactivation reported in the United States Food and Drug Administration Manufacturer and User Facility Device Experience Database. Heart Rhythm, 2004. 1(4): p. 399–405.PubMedCrossRefGoogle Scholar
  208. 208.
    Mueller, P.S., C.C. Hook, and D.L. Hayes, Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life. Mayo Clin Proc, 2003. 78(8): p. 959–63.CrossRefGoogle Scholar
  209. 209.
    McClellan, M.B. and S.R. Tunis, Medicare coverage of ICDs. N Engl J Med, 2005. 352(3): p. 222–4.PubMedCrossRefGoogle Scholar
  210. 210.
    Kuppermann, M., et al., An analysis of the cost effectiveness of the implantable defibrillator. Circulation, 1990. 81(1): p. 91–100.PubMedGoogle Scholar
  211. 211.
    Kupersmith, J., et al., Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J, 1995. 130(3 Pt 1): p. 507–15.PubMedCrossRefGoogle Scholar
  212. 212.
    Zwanziger, J., et al., The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol, 2006. 47(11): p. 2310–8.PubMedCrossRefGoogle Scholar
  213. 213.
    Sanders, G.D., M.A. Hlatky, and D.K. Owens, Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med, 2005. 353(14): p. 1471–80.CrossRefGoogle Scholar
  214. 214.
    Mushlin, A.I., et al., The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation, 1998. 97(21): p. 2129–35.Google Scholar
  215. 215.
    Al-Khatib, S.M., et al., Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med, 2005. 142(8): p. 593–600.PubMedGoogle Scholar
  216. 216.
    Mark, D.B., et al., Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation, 2006. 114(2): p. 135–42.PubMedCrossRefGoogle Scholar
  217. 217.
    Actuarial risk of sudden death while awaiting cardiac transplantation in patients with atherosclerotic heart disease. DEFIBRILAT Study Group. Am J Cardiol, 1991. 68(5): p. 545–6.Google Scholar
  218. 218.
    Uretsky, B.F. and R.G. Sheahan, Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol, 1997. 30(7): p. 1589–97.PubMedCrossRefGoogle Scholar
  219. 219.
    Dreifus, L.S., et al., Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation). J Am Coll Cardiol, 1991. 18(1): p. 1–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Salam Sbaity
    • 1
  • Brian Olshansky
    • 2
  1. 1.Department of Internal MedicineUniversity of Iowa Hospitals and ClinicsIowaUSA
  2. 2.University of Iowa HospitalIowaUSA

Personalised recommendations